A polymorphism, L162V, in the peroxisome proliferator-activated receptor α (PPARα) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus

Journal of Molecular Medicine

Volumn 79, Issue 4, 2001, Pages 198-204

  Evans, David ^a,d   Aberle, J ^a   Wendt, D ^a   Wolf, A ^b   Beisiegel, U ^a   Mann, W Alexander ^a,c,e  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Evangelisches/Johanniter Klinikum   (Germany)

^c Mediclin AG   (Germany)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Obesity; PPAR polymorphism; Type 2 DM

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ADULT; AGED; ALLELE; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; FEMALE; GENETIC PREDISPOSITION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY;

ADULT; AGED; ANIMALS; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; HUMANS; HYPERLIPIDEMIAS; LIPIDS; MALE; MIDDLE AGED; OBESITY; OBESITY, MORBID; POLYMORPHISM, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 0035037401     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090100189     Document Type: Article

References (11)

1. Pineda Torra I, Gervois P, Staels B (1999) Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and ageing. Curr Opin Lipidol 10:151-159
2. Fruchart JC, Duriez P, Staels B (1999) Peroxisome proliferator-activated receptor alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 10:245-257
3. Costet P, Legendres C, More J, Edgar A, Galtier P, Pineau T (1998) Peroxisome proliferator-activated receptor α-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem 273:29577-29585
4. Chaput E, Saladin R, Silvestre M, Edgar AD (2000) Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun 271:445-450
5. Flavell DM, Pinneda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE (2000) Variation in the PPARα gene is associated with altered function in vivo and plasma lipid concentrations in type II diabetic subjects. Diabetologia 43:673-680
6. Vohl MC, Lepage P, Gaudet D, Brewer CG, Betard C, Perron P, Houde G, Cellier C, Faith JM, Despres J, Morgen K, Hudson TJ (2000) Molecular scanning of the human PPARα gene: association of the L162 V mutation with hyperapobetalipoproteinemia. J Lipid Res 41:945-952
7. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539-553
8. Vos P, Lefebvre A, Miller SG, Guerre-Millo M, Wong K, Salidin R, Hammann LG, Staels B, Brigs MR, Auwerx J (1996) Thiazolodinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ. J Clin Invest 98:1004-1009
9. Dachet C, Cavallero E, Martin C, Girardot G, Jacotot B (1995) Effect of gemfibrozil on the concentration and composition of very low density and low density lipoprotein subfractions in hypertriglyceridmeic patients. Atherosclerosis 113:1-9
10. Avogaro A, Beltramello P, Marin R, Zambon S, Bonanome A, Biffanti S, Confortin L, Manzato E, Crepaldi G, Tiengo A (1995) Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients. Atherosclerosis 113:117-127
11. Roduit R, Morin J, Masse F, Segall L, Roche E, Newgard CB, Assimacopoulos-Jeannet F, Prentki M (2000) Glucose down- regulates the expression of the PPARα gene in the pancreatic β-cell. J Biol Chem (in press)